Halozyme Therapeutics (HALO) Scheduled to Post Earnings on Thursday

Halozyme Therapeutics (NASDAQ:HALO) will issue its quarterly earnings data after the market closes on Thursday, October 31st. Analysts expect the company to announce earnings of $0.93 per share for the quarter. Halozyme Therapeutics has set its FY24 guidance at $3.65-4.05 EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. The business had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.68 EPS. On average, analysts expect Halozyme Therapeutics to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Halozyme Therapeutics Stock Up 2.5 %

Shares of NASDAQ HALO opened at $50.46 on Tuesday. The company’s 50 day moving average price is $57.99 and its 200-day moving average price is $51.67. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41. Halozyme Therapeutics has a 52-week low of $33.07 and a 52-week high of $65.53. The company has a market capitalization of $6.42 billion, a P/E ratio of 20.85, a price-to-earnings-growth ratio of 0.50 and a beta of 1.27.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on HALO. Benchmark restated a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. HC Wainwright reissued a “buy” rating and issued a $65.00 price objective on shares of Halozyme Therapeutics in a research note on Friday. TD Cowen raised their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Morgan Stanley lifted their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Finally, Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.44.

Insider Activity

In related news, Director Matthew L. Posard sold 10,000 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $55.72, for a total value of $557,200.00. Following the transaction, the director now directly owns 89,755 shares in the company, valued at $5,001,148.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Matthew L. Posard sold 9,881 shares of the stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the sale, the director now directly owns 69,874 shares of the company’s stock, valued at $4,031,729.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Matthew L. Posard sold 10,000 shares of the stock in a transaction on Monday, August 12th. The shares were sold at an average price of $55.72, for a total value of $557,200.00. Following the completion of the sale, the director now directly owns 89,755 shares of the company’s stock, valued at $5,001,148.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 89,881 shares of company stock worth $5,169,834 over the last quarter. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.